Study: Glomerulonephritis recurrence varies in patients with a kidney transplant
Click Here to Manage Email Alerts
Key takeaways:
- Overall, 15.3% of patients had glomerulosclerosis recurrence during follow-up.
- In addition, 20.5% of patients had death-censored graft loss.
PHILADELPHIA — Recurrent glomerulonephritis and long-term graft survival vary in certain patients who had a kidney transplant, data presented at the American Transplant Congress shows.
“[Glomerulonephritis (GN) recurrence is an important cause of death-censored graft loss,” Romain Brousse, MD, MSc, of the Paris Institute for Transplantation and Organ Regeneration, said in a presentation. “Only a limited number of studies have evaluated the impact of native kidney disease reoccurrence on allograft survival.”
Researchers conducted a prospective, phenotyped cohort study to investigate glomerulonephritis recurrence. The population-based study looked to evaluate long-term allograft survival outcomes in patients with recurrent glomerulonephritis who had received a kidney transplant.
Investigators examined 4,986 patients enrolled in a French multicentric, unselected development cohort from 2005 to 2014. Patients were followed until 2017.
Researchers tracked patient history on initial kidney disease, and each allograft biopsy performed during follow-up was noted for lesions and diagnoses. Data defined relapse as the presence on graft biopsy of lesions upon light microscopy or glomerular immune deposits in immunofluorescence study, which were consistent with the initial disease.
According to the results, 835 patients were transplanted for a documented native kidney glomerulonephritis at high recurrence risk, with most having IgA nephropathy (IgAN), primary focal segmental glomerulosclerosis (FSGS), membranoproliferative glomerulonephritis (MPGN) or membranous nephropathies (MN).
Among them, 128 patients (15.3%) had glomerulosclerosis recurrence during follow-up, with recurrence occurring in a median 8 months, with variable proportion of relapse.
During follow-up, 171 patients (20.5%) had death-censored graft loss. The impact of recurrence on long-term graft survival varied among glomerulosclerosis categories, with particularly poor outcomes in patients with recurrent primary FSGS or MPGN.
The findings underline the “potential to help decision-making in such a setting and to be used in clinical trials for recurrent GN,” Brousse said.
Collapse
Brousse R, et al. Poster 1079. Presented at: American Transplant Congress; June 1-5, 2024; Philadelphia.
Read more about
Click Here to Manage Email Alerts